MET and breast carcinoma: Blocking the MUC5AC/c-MET/CD44v6 complex with a blood–brain barrier-permeable c-MET inhibitor, bozitinib, effectively reduces MUC5AC expression and decreases the metastatic potential of breast cancer cells to the brain [30].